

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Madaline Chirica, et al.

Application No.: Not yet known.

Filed: Herewith


For: MAMMALIAN RECEPTOR  
PROTEINS; RELATED  
REAGENTS AND METHODS

Examiner: Not yet known.

Art Unit: Not yet known.

"Express Mailing" mailing label number EL 982 851 001 US  
Date of Deposit: November 21 2003I hereby certify that this correspondence is being deposited with  
the United States Postal Service "Express Mail Post to  
Addressee" service under 37 CFR 1.10 on the date indicated  
above and is addressed to: Mail Stop Patent Application,  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450.

by:

  
Tom BrodyMail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Honorable Sir:

In order to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, for the above-identified application, in accordance with 37 C.F.R. §§1.821-1.825, Applicants hereby submit: (1) a write-protected diskette containing a computer-readable submission for the "Sequence Listing;" and (2) a "Sequence Listing" paper copy of the contents of the diskette.

REMARKS

Enclosed is a write-protected floppy diskette with the sequence listing generated by the Patent Office's PATENTIN program. The diskette should comply with the requirements of 37 C.F.R. §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS

operating system. If the diskette is damaged, please call Applicants and a replacement diskette will be provided. A paper copy printout of the diskette is attached thereto.

I hereby state that the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§1.821(c) and (e), respectfully, are believed to be the same. This submission introduces no new matter, since the enclosed sequences are all disclosed in the Sequence Listing submitted in the priority document, U.S. Ser. No. 09/853,180, filed May 10, 2001.

Applicants have invested significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application in full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 C.F.R. §1.135(c).

Applicants believe that no fees are required; however, if any fees are required with the present submission, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

Date: November 21, 2003

By: Tom Brody  
Tom Brody  
Agent for Applicants  
Reg. No. 46,433

**Customer No. 028008**  
DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200

Enclosed: Paper copy of the present Sequence Listing (15 pages).